miRNA EV expression was lower at D14 in patients who later developed aGvHD compared with those who did not and this was significant for miR-199 ( p = 0.008), miR-93* ( p = 0.001), and approaching significance for miR-423 ( p = 0.09) (Figure 4 A).
Although differential expression of the miR-423 and miR-199 (miR-93* was not present on the codeset) candidate miRNAs was confirmed, additional species with highly significant differential expression were also identified, suggesting that a panel of signature miRNA biomarkers may be a more potent predictor of aGvHD incidence and severity for this complex disease.